The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between molecular changes and perioperative immunotherapy in patients with advanced clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
 
Wadih Issa
No Relationships to Disclose
 
Navneet Kaur
No Relationships to Disclose
 
Andrew DeVilbiss
No Relationships to Disclose
 
Ze Yu
No Relationships to Disclose
 
Qinhan Zhou
No Relationships to Disclose
 
Damla Gunenc
No Relationships to Disclose
 
Chao Xing
No Relationships to Disclose
 
Andrew Wang
Leadership - Archimmune Therapeutics; Capio BioSciences; Nanorobotics; Novartis (I)
Stock and Other Ownership Interests - Archimmune Therapeutics; Archimmune Therapeutics; Capio BioSciences
Consulting or Advisory Role - Aptitude Health (I); Aravive (I); AVEO (I); Bayer (I); Capio BioSciences; Dendreon (I); Eisai (I); Gerson Lehrman Group; Janssen (I); Kidney Cancer Association (I); Merck KGaA (I); Mirati Therapeutics (I); MJH Associates (I); Peerview (I); PlatformQ Health (I); QED Therapeutics (I); Regeneron (I); Sanofi/Aventis (I); Seagen (I)
Research Funding - Archimmune Therapeutics; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Biomatrix patent licensed to PhoenixSongs
Travel, Accommodations, Expenses - Exelixis (I); Genentech (I); Pfizer (I); Sanofi (I)
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; Mashup Media; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Sanofi/Aventis; Seagen; Xencor
Research Funding - ALX Oncology (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); OncoC4; Pfizer (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Bayer
Other Relationship - ASCO; Kidney Cancer Association; KidneyCan; Myrovlytis Trust; Winn Foundation